Active, not recruitingPHASE1, PHASE2NCT04083599
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
Studying Small cell lung cancer
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Genmab
- Principal Investigator
- Study OfficialGenmab
- Intervention
- GEN1042(biological)
- Enrollment
- 350 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2019 – 2026
Study locations (30)
- Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States
- Cancer & Blood Specialty Clinic, Los Alamitos, California, United States
- Moores Cancer Center at the UC San Diego Health, San Diego, California, United States
- Yale University Cancer Center, New Haven, Connecticut, United States
- ChristianaCare, Newark, Delaware, United States
- Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States
- Florida Cancer Affiliates, Ocala, Florida, United States
- Hope and Healing Cancer Services, Hinsdale, Illinois, United States
- University of Kentucky, Lexington, Kentucky, United States
- Norton Cancer Institute, Louisville, Kentucky, United States
- Maryland Oncology Hematology PA, Columbia, Maryland, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- Levine Cancer Center, Charlotte, North Carolina, United States
- Novant Health Cancer Institute - Forsyth (Medical Oncology), Winston-Salem, North Carolina, United States
- Kaiser Permanente (KP) Oncology/Hematology, Portland, Oregon, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
BioNTech SE
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04083599 on ClinicalTrials.govOther trials for Small cell lung cancer
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT06694454Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)National Cancer Institute (NCI)
- RECRUITINGNANCT07398599Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II StudySecond Affiliated Hospital of Nanchang University
- RECRUITINGPHASE1, PHASE2NCT07480213Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)Beijing Biotech
- RECRUITINGPHASE1, PHASE2NCT07227597A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)Merck Sharp & Dohme LLC
- RECRUITINGPHASE1NCT07348211First in Human Study of SIM0610 in Solid TumorsJiangsu Simcere Pharmaceutical Co., Ltd.
- RECRUITINGNANCT07161310Urolithin A in Patients With Previously Untreated Solid Tumors Receiving Immune Checkpoint InhibitorsGoethe University
- RECRUITINGPHASE2NCT07304739Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal MetastasesTianjin Medical University Cancer Institute and Hospital
- RECRUITINGPHASE3NCT07185997Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon MutationsArriVent BioPharma, Inc.